Seven Talking Points At ASH 2019
Bispecifics Emerge To Challenge CAR-Ts
Executive Summary
The tireless pace of change in hemato-oncology was showcased in Orlando.
You may also be interested in...
Gilead Calls Forty Seven Buyout Complementary To Kite, Other IO Efforts
Gilead will pay $4.9bn to acquire Forty Seven and its potential first-in-class anti-CD47 agent magrolimab. A fast-track development effort in myelodysplastic syndrome will be the initial focus for that asset.
Finance Watch: IPOs Are In A Slump, But Already Public Companies Have Rallied
Public Company Edition: The last biopharma initial public offering in the US was on 11 November, but follow-on and other offerings are generating hundreds of millions of dollars. Among RNA drug developers, Ionis issued more than $500m in new debt, while Arrowhead raised $266.8m.
AstraZeneca's Calquence Steps Up in First-Line CLL
A PFS benefit and favorable tolerability profile associated with AstraZeneca’s BTK inhibitor acalabrutinib used first-line in CLL, when given alone or combined with obinutuzumab, may serve it well against entrenched competitors and BTK inhibitors in clinical development.